A recent study conducted at the University of Padua in Italy focused on using machine learning to select highly productive cell lines for biopharmaceutical processes. The research emphasized the importance of metabolomics data in identifying cell lines with high productivity and product quality attributes. The study highlighted the role of specific metabolic pathways, such as the tricarboxylic acid cycle and amino/nucleotide sugar pathways, in influencing monoclonal antibody productivity. Financial support for the research was provided by GSK R&D, Biopharm Product Development and Supply. [Extracted from the article]
A patent was issued for manufacturing methods for producing anti-TNF antibody compositions by Janssen Biotech Inc. The patent focuses on the development of anti-TNF antibodies to target TNF alpha, which is associated with inflammatory diseases, autoimmune diseases, infections, and malignancies. The antibodies are expressed in Chinese Hamster Ovary cells and aim to reduce immunogenicity and improve therapeutic benefits for diseases like rheumatoid arthritis and Crohn's disease. The patent outlines specific amino acid sequences and oligosaccharide profiles for the anti-TNF antibodies to enhance their efficacy and reduce adverse effects. [Extracted from the article]
A patent has been issued to Regeneron Pharmaceuticals Inc. for methods to improve cell culture performance and reduce asparagine sequence variants in the production of recombinant proteins. The patent outlines strategies for supplementing asparagine in defined cell culture media during early and late fed-batch cell culture stages to enhance cell growth and protein yield. The invention aims to optimize cell culture conditions for the production of high-quality therapeutic proteins, addressing the need for improved methods in biopharmaceutical manufacturing. [Extracted from the article]
A patent has been issued for anti-tumor necrosis factor (TNF) antibodies and compositions by Janssen Biotech Inc. The patent focuses on the development of anti-TNF antibodies expressed in Chinese Hamster Ovary cells to target TNF alpha, which is associated with inflammatory diseases, autoimmune diseases, infections, and malignancies. The invention aims to provide therapeutic options for diseases mediated by TNF alpha, such as rheumatoid arthritis and Crohn's disease, by reducing immunogenicity and improving efficacy. [Extracted from the article]
A Phase 1 clinical trial in Australia is being conducted to evaluate the safety, reactogenicity, and immunogenicity of a Bivalent Recombinant Respiratory Syncytial Virus (RSV) Vaccine (CHO Cell) (SCB-1019T) in children aged 2 to <6 years. The study will assess four formulations of the vaccine at two escalating doses, with a placebo used as a control due to the lack of a licensed RSV comparator vaccine for young children globally. The trial aims to gather data on safety and immunogenicity to inform further clinical development of the vaccine. [Extracted from the article]
The article discusses a randomized, double-blind Phase III clinical trial evaluating the lot-to-lot consistency of three consecutive batches of recombinant herpes zoster vaccine (CHO cell) in subjects aged 40 years and older. The trial aims to assess the consistency of the vaccine's production lots and their impact on subjects after receiving two doses on a 0, 2-month schedule. The study involves 1200 subjects and focuses on measuring anti-gE antibody levels and monitoring adverse events following vaccination. The trial is set to be completed by May 1, 2025, and is being conducted in China. [Extracted from the article]
Researchers at the Agency for Science Technology and Research (ASTAR) have developed and characterized a comprehensive panel of CHO cell glycosylation mutants to advance glycobiology and biotechnology research. The study focused on the effects of mutated glycogenes on model molecules like EPO-Fc and trastuzumab, analyzing their N-glycans using LC-MS/MS. The research highlighted the impact of Fc N-glycans on antibody interactions and antibody-dependent cellular cytotoxicity, as well as the potential for glycoengineered production of therapeutic proteins. The study provides insights into the role of glycans in antibody interactions and therapeutic efficacy, offering valuable contributions to the fields of immunology and biotechnology. [Extracted from the article]
PATENT applications, RESEARCH personnel, AFFINITY chromatography, CHEMICAL stability, COMPLEMENT (Immunology), BLOOD proteins, ECULIZUMAB, TEETH polishing, TITERS
Abstract
The article reports on a new patent application titled "Manufacturing Optimization Of GL-2045, A Multimerizing Stradomer," which was filed on September 7, 2023, and made publicly available on August 22, 2024. It discusses about GL-2045 which is a recombinant mimetic of pooled human intravenous immunoglobulin (IVIG) designed to offer enhanced efficacy for treating autoimmune diseases compared to traditional IVIG.
The US Patent and Trademark Office has published a patent application titled "Composition and Method" by inventors Arunakumari Alahari and Rosanne Dunn. The application, filed by HaemaLogiX Pty Ltd, focuses on purifying binding proteins, specifically antibodies, from unwanted components in cell culture fluid. The method involves incorporating a basic wash step into the protein purification process, resulting in higher yields of unbound binding proteins and higher purity compositions. The patent application provides detailed examples and claims for the method and its applications, including the production of antibodies using CHO cells for pharmaceutical development and other medical treatments, as well as their potential use in nasal lubricants, irrigations, and respiratory agents. [Extracted from the article]
Researchers from HaemaLogiX Ltd. have submitted a patent application for a method of purifying binding proteins, such as monoclonal antibodies, from undesirable components in cell culture fluid. The method involves incorporating a basic wash step into the protein purification process, which allows for higher yields of unbound binding protein and higher purity compositions. The patent application also includes information on the composition of the binding proteins and the specific steps involved in the purification process. This research has implications for the production of therapeutic biologics and diagnostic tools. [Extracted from the article]
Researchers at Volgograd State Medical University in Russia have conducted experimental studies on new azoloazine derivatives for the treatment of breast cancer. The goal of the research was to assess the antitumor activity of these derivatives in vitro and in vivo. The results showed that certain compounds exhibited high cytotoxicity against breast cancer cells while having low cytotoxicity against normal cells. The researchers concluded that these derivatives have potential as chemotherapeutic agents and warrant further investigation for the development of new antitumor drugs. [Extracted from the article]
CHO cell, CELL lines, BIOTECHNOLOGY, BIOTECHNOLOGY industries, PHARMACEUTICAL biotechnology industry
Abstract
A report from Boehringer Ingelheim Pharma GmbH & Co. KG in Biberach, Germany discusses the development of responsive promoters and their use in stable Chinese hamster ovary (CHO) sensor cell lines. CHO cells are commonly used in biotechnology to produce recombinant proteins, and it is important to monitor and adjust bioprocess parameters for proper protein expression. The report describes the procedure for generating responsive promoters that react to limiting conditions and the creation of stable sensor cell lines. These cell lines can communicate with the operator and trigger the expression of a minimal CMV promoter. The research concludes that an automated sampling system coupled with a fluorescence microscope allows for continuous observation of CHO cells and can detect increasing amounts of a specific fluorescent protein to report emerging limiting conditions. [Extracted from the article]
This article discusses the challenges faced in the field of microrobotics, particularly in developing a control system for precise manipulation and navigating robots in densely populated environments. The researchers in this study fabricated Mazebot microrobots using silica spheres and ferromagnetic coating, and used them to create cellbots with genetically modified Chinese Hamster Ovary (CHO) cells. They successfully navigated both the Mazebots and cellbots through a dense environment populated by CHO cells, demonstrating the functionality of their algorithm and its potential for biomedical applications. The biocompatibility of the Mazebots was confirmed through exposure to CHO cells for 24 hours. However, it is important to note that this preprint has not been peer-reviewed. [Extracted from the article]
A study conducted by researchers at Mashhad University of Medical Sciences compared the ability of two different materials, Gum Arabic and Poly Anionic Cellulose, to biosynthesize selenium nanoparticles (SeNPs) and protect Chinese Hamster Ovary (CHO) cells against radiation damage. The researchers found that Se-GA nanoparticles had antioxidant properties and significantly increased the radioprotective effect on CHO cells compared to the control group. On the other hand, Se-PAC did not show a significant increase in radioprotection. The study suggests that Se-GA nanoparticles have potential as a radioprotector. [Extracted from the article]
A preprint abstract from biorxiv.org discusses a study on angiotensin-(1-5) (Ang-(1-5)), a fragment of angiotensin II, and its biological activity. The study investigates the effects of Ang-(1-5) on nitric oxide release, vasodilation, and blood pressure. The results show that Ang-(1-5) activates eNOS and increases NO release in certain cells, induces relaxation of constricted arteries, and lowers blood pressure in mice. The study concludes that Ang-(1-5) is a potent endogenous AT2-receptor agonist. However, it is important to note that this preprint has not been peer-reviewed. [Extracted from the article]
A patent application by F. Hoffmann-La Roche Inc. outlines a method for modifying the glycosylation of antibodies in vitro. The method involves binding the antibodies to a solid phase and then using glycosylation modifying enzymes to alter the glycosylation. This process can be applied to different types of antibodies and allows for the production of antibodies with specific and controlled glycosylation patterns. The modified antibodies can be recovered and purified for further use. This method is cost-effective and can be easily integrated into existing antibody purification processes. [Extracted from the article]
A study conducted at the National Autonomous University of Mexico (UNAM) has found that proteolysis, a common problem during recombinant protein production, can be prevented by expressing a bacterial biosynthetic pathway in CHO cells. The researchers discovered that the expression of the livipeptin biosynthetic pathway in CHO cells resulted in the production of a protease inhibitor without adverse effects on cell growth or viability. This finding expands the field of metabolic engineering of mammalian cells and offers a new option for proteolysis inhibition in bioprocess engineering. The research has been peer-reviewed and published in the journal Metabolic Engineering. [Extracted from the article]
A recent study conducted by researchers at Xinxiang Medical University in China explored the use of synthetic enhancers to improve the production of recombinant therapeutic proteins (RTPs) in CHO cells. The researchers evaluated five synthetic enhancers, including multiple transcription factor regulatory elements (TFREs), and found that four of them significantly enhanced the expression of report genes in both transient and stably transfected CHO cells. The study also investigated the effect of these enhancers on human serum albumin (HSA) and found that they increased transient expression by up to 1.5 times and stable expression by up to 2.14 times. The researchers concluded that optimizing enhancers in the CMV promoter could increase the production yield of transgenes in CHO cells, which is important for developing high-yield CHO cell expression systems. [Extracted from the article]
A patent application by inventor Joan-Carles ARCE has been made available online for a composition and method for controlled ovarian stimulation (COS) in the approval process with the US Patent and Trademark Office. The patent application, assigned to Ferring B.V., focuses on individualized dosing regimens for COS using recombinant follicle stimulating hormone (FSH). The invention aims to reduce the risk of ovarian hyperstimulation syndrome (OHSS) and improve pregnancy outcomes by tailoring the dosage of FSH based on factors such as anti-Mullerian hormone (AMH) levels and previous ovarian response. Clinical trials have shown that the use of the human cell line-derived rFSH, REKOVELLE, increases the probability of live birth and reduces early pregnancy loss compared to CHO cell-derived rFSH. This patent application discusses compositions and methods for controlled ovarian stimulation in the treatment of infertility, specifically targeting female patients aged 30 to 40 years. The recombinant FSH, with specific sialylation patterns, is administered at different doses depending on the patient's age and serum anti-Müllerian hormone (AMH) level. The goal is to increase the probability of live birth and reduce the likelihood of early pregnancy loss. The patent application provides detailed claims and additional information for further exploration. [Extracted from the article]
A study conducted at Kyushu University in Fukuoka, Japan, explores the use of artificial genes in the production of therapeutic antibodies. The researchers aimed to develop a high-production system using a synthetic biology approach by designing a gene expression system based on an artificial transcription factor. They successfully produced a model antibody using this system, achieving high-titer antibody production at the gram-per-liter level. The study suggests that this artificial gene expression system could be a powerful tool for constructing high-yield production systems in CHO cells. [Extracted from the article]
CHO cell, PATENTS, CELL culture, COMPLEMENT (Immunology), AUTOIMMUNE diseases
Abstract
Gliknik Inc. has been granted a patent for an optimized manufacturing method of GL-2045, a recombinant mimetic of intravenous immunoglobulin (IVIG) used in the treatment of autoimmune diseases. The method involves culturing CHO cells, adjusting growth temperature, and utilizing purification techniques to improve cell viability, protein titer, and the percentage of higher-order multimers in GL-2045. The patent also describes a composition comprising a recombinantly produced homodimer and a multimer of the homodimer, which is effective in treating inflammatory, autoimmune, or infectious diseases. The patent was filed by Gliknik Inc. and published in October 2023. [Extracted from the article]
"It has further been found that an antibody light chain affinity ligand bound antibody can be effectively enzymatically modified as if the antibody would be in solution." Therefore, antibodies produced in recombinant expression systems can be considered a "population of antibodies" (a term that is further used herein), with antibodies being identical in their amino acid sequence but exhibiting heterogeneity with respect to the N-linked glycan pattern of their Fc-region. While further non-conserved glycosylation sites may be present within the Fab region of an antibody, the influence of antibody glycosylation on its effector functions has been attributed to Fc-region glycosylation. The method of claim 1, wherein the antibody is a bivalent monospecific antibody or a bivalent bispecific antibody or an antibody Fab fragment. [Extracted from the article]
The nucleic acid or nucleic acids of claim 11, wherein the nucleic acid or nucleic acids encodes the heavy chain variable region and the light chain variable region of the antibody or antibody fragment that specifically binds to hOX40L. The nucleic acid or nucleic acids of claim 1, wherein the nucleic acid or nucleic acids encodes the heavy chain and the light chain of the antibody that specifically binds to hOX40L. [Extracted from the article]
SCIENCE journalism, CHO cell, MONOCLONAL antibodies, AGRICULTURE, IMMUNOGLOBULINS
Abstract
Herein, we successfully expressed ASFV p17 in CHO cells using a suspension culture system and generated a monoclonal antibody (mAb) against p17. Keywords: Shanghai; People's Republic of China; Asia; Antibodies; Blood Proteins; CHO Cells; Cell Line; Cell Research; Immunoglobulins; Immunology; Immunoproteins; Monoclonal Antibodies; Monoclonal Antibody; Proteins EN Shanghai People's Republic of China Asia Antibodies Blood Proteins CHO Cells Cell Line Cell Research Immunoglobulins Immunology Immunoproteins Monoclonal Antibodies Monoclonal Antibody Proteins 2 2 1 08/28/23 20230828 NES 230828 2023 AUG 28 (NewsRx) -- By a News Reporter-Staff News Editor at Veterinary Week -- New research on Proteins - Antibodies is the subject of a report. [Extracted from the article]
Keywords: Antibodies; Bioengineering; Biotechnology; Blood Proteins; CHO Cells; Cell Line; Cell Research; Drugs and Therapies; Gene Therapy; Genetics; Immunoglobulins; Immunology; Proteins EN Antibodies Bioengineering Biotechnology Blood Proteins CHO Cells Cell Line Cell Research Drugs and Therapies Gene Therapy Genetics Immunoglobulins Immunology Proteins 1880 1880 1 08/21/23 20230825 NES 230825 2023 AUG 25 (NewsRx) -- By a News Reporter-Staff News Editor at Gene Therapy Weekly -- Data detailed on gene therapy have been presented. Antibodies, Bioengineering, Biotechnology, Blood Proteins, CHO Cells, Cell Line, Cell Research, Drugs and Therapies, Gene Therapy, Genetics, Immunoglobulins, Immunology, Proteins. [Extracted from the article]
Keywords: Antibodies; Blood Proteins; CHO Cells; Cell Line; Cell Research; Immunoglobulins; Immunology; Proteins EN Antibodies Blood Proteins CHO Cells Cell Line Cell Research Immunoglobulins Immunology Proteins 5365 5365 1 06/12/23 20230616 NES 230616 2023 JUN 16 (NewsRx) -- By a News Reporter-Staff News Editor at Health & Medicine Week -- Investigators publish new report on immunoglobulins. Antibodies, Blood Proteins, CHO Cells, Cell Line, Cell Research, Immunoglobulins, Immunology, Proteins. [Extracted from the article]
Hangzhou, People's Republic of China, Asia, Biochemicals, Biochemistry, Biomarkers, CHO Cells, Cell Line, Cell Research, Chemicals, Diagnostics and Screening, Health and Medicine Keywords: Hangzhou; People's Republic of China; Asia; Biochemicals; Biochemistry; Biomarkers; CHO Cells; Cell Line; Cell Research; Chemicals; Diagnostics and Screening; Health and Medicine EN Hangzhou People's Republic of China Asia Biochemicals Biochemistry Biomarkers CHO Cells Cell Line Cell Research Chemicals Diagnostics and Screening Health and Medicine 6862 6862 1 06/05/23 20230609 NES 230609 2023 JUN 9 (NewsRx) -- By a News Reporter-Staff News Editor at Health & Medicine Week -- Current study results on Diagnostics and Screening - Biomarkers have been published. [Extracted from the article]
A seropositive subject is a subject whose antibody concentration is greater than or equal to the cut-off value.
•Geometric mean concentration (GMC) of anti-VZV antibody [ Time Frame: At 6, 12 and 24 months after the last vaccination ] -- measured by ELISA.
•Seropositivity rate of anti-VZV antibody [ Time Frame: At 6, 12 and 24 months after the last vaccination ] -- The seropositivity rate is defined as the percentage of seropositive subjects. [Extracted from the article]
CHO cell, MANUFACTURING cells, CELL lines, BIOTECHNOLOGY, LOCUS (Genetics)
Abstract
Biberach, Germany, Europe, Animal Health Companies, Biopharmaceutical Companies, Business, CHO Cells, Cell Line, Cell Research, Healthcare Biotechnology Companies Keywords: Biberach; Germany; Europe; Animal Health Companies; Biopharmaceutical Companies; Business; CHO Cells; Cell Line; Cell Research; Healthcare Biotechnology Companies EN Biberach Germany Europe Animal Health Companies Biopharmaceutical Companies Business CHO Cells Cell Line Cell Research Healthcare Biotechnology Companies 9 9 1 04/03/23 20230403 NES 230403 2023 APR 3 (NewsRx) -- By a News Reporter-Staff News Editor at Veterinary Week -- New research on Biotechnology is the subject of a report. [Extracted from the article]
Exclusion Criteria: Positive results of SARS-CoV-2 RT-PCR within 24 hours; The subject has a history of SARS-CoV-2 infection within 3 months; The anti-SARS-CoV-2 IgM antibody was positive during the screening period. [Extracted from the article]
Moreover, this soluble anti-PD-1 scFv variant disrupted the interaction between PD-1 expressed on Jurkat Cells and PD-L1 expressed on CHO cells." We previously reported the isolation of a single chain variable fragment (scFv) of the monoclonal anti-PD-1 antibody Nivolumab, that binds to purified PD-1 and blocked its interaction with PD-L1 [4]." Keywords: Boston; State:Massachusetts; United States; North and Central America; CHO Cells; Cell Line; Cell Research; Drugs and Therapies; Health and Medicine; Immunologic Agents; Immunotherapy; Monoclonal Antibodies; Nivolumab Therapy; Pharmaceuticals EN Boston State:Massachusetts United States North and Central America CHO Cells Cell Line Cell Research Drugs and Therapies Health and Medicine Immunologic Agents Immunotherapy Monoclonal Antibodies Nivolumab Therapy Pharmaceuticals 658 658 1 03/23/23 20230314 NES 230314 2023 MAR 17 (NewsRx) -- By a News Reporter-Staff News Editor at Immunotherapy Weekly -- Investigators publish new report on Drugs and Therapies - Monoclonal Antibodies. [Extracted from the article]
CHO cell, SARS-CoV-2, IMMUNE response, SARS-CoV-2 Delta variant, COVID-19
Abstract
Keywords: Antibodies; Biological Products; Blood Proteins; CHO Cells; COVID-19; Cell Line; Cell Research; Coronavirus; Glycoconjugates; Glycoproteins; Health and Medicine; Immunization; Immunoglobulins; Immunology; Peptides and Proteins; Proteins; RNA Viruses; Risk and Prevention; SARS-CoV-2; Severe Acute Respiratory Syndrome Coronavirus 2; Vaccines; Viral; Virology EN Antibodies Biological Products Blood Proteins CHO Cells COVID-19 Cell Line Cell Research Coronavirus Glycoconjugates Glycoproteins Health and Medicine Immunization Immunoglobulins Immunology Peptides and Proteins Proteins RNA Viruses Risk and Prevention SARS-CoV-2 Severe Acute Respiratory Syndrome Coronavirus 2 Vaccines Viral Virology 2023 MAR 12 (NewsRx) -- By a News Reporter-Staff News Editor at NewsRx COVID-19 Weekly -- Investigators publish new report on COVID-19. For more information on this research see: Antigenicity and immunogenicity of SARS-CoV-2 surface glycoprotein fragment in CHO cells. [Extracted from the article]
Dublin, Ireland, Europe, Life Science, CHO Cells, Cell Line, Cell Research Keywords: Dublin; Ireland; Europe; Life Science; CHO Cells; Cell Line; Cell Research EN Dublin Ireland Europe Life Science CHO Cells Cell Line Cell Research 369 369 1 03/24/23 20230224 NES 230224 2023 FEB 24 (NewsRx) -- By a News Reporter-Staff News Editor at Drug Week -- Research findings on Life Science are discussed in a new report. Keywords for this news article include: Dublin, Ireland, Europe, Life Science, CHO Cells, Cell Line, Cell Research, University College Dublin. [Extracted from the article]
The composition of claim 9, wherein the heparan sulfate has increased heparan sulfate polymerization, increased heparan sulfate sulfation, increased epimerization of uronic acid in heparan sulfate, increased N-sulfation of heparan sulfate, and/or increased O-sulfation of heparan sulfate compared to a heparan sulfate from a wild-type CHO cell." The composition of claim 1, wherein the composition is derived from a cell line genetically modified to be deficient for chondroitin sulfate synthase 1 (ChSy). [Extracted from the article]
Abstract: A model was developed for novel prediction of N-linked glycan branching pattern classification for CHO-derived N-linked glycoproteins. The model consists of 30 independent recurrent neural networks and uses predicted quantities of secondary structure elements and residue solvent accessibility as an input vector. The model was designed to predict the major component of a heterogeneous mixture of CHO-derived glycoforms of a recombinant protein under normal growth conditions. Resulting glycosylation prediction is classified as either complex-type or high mannose. The incorporation of predicted quantities in the input vector allowed for theoretical mutant N-linked glycan branching predictions without initial experimental analysis of protein structures. Primary amino acid sequence data were effectively eliminated from the input vector space based on neural network prediction analyses. This provided further evidence that localized protein secondary structure elements and conformational structure may play more important roles in determining glycan branching patterns than does the primary sequence of a polypeptide. A confidence interval parameter was incorporated into the model to enable identification of false predictions. The model was further tested using published experimental results for mutants of the tissue-type plasminogen activator protein [J. Wilhelm, S.G. Lee, N.K. Kalyan, S.M. Cheng, F. Wiener, W. Pierzchala, P.P. Hung, Alterations in the domain structure of tissue-type plasminogen activator change the nature of asparagine glycosylation. Biotechnology (N.Y.) 8 (1990) 321–325]. [Copyright &y& Elsevier]